Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1985 1
1988 2
1989 2
1990 1
1992 1
1993 3
2008 1
2014 4
2015 8
2016 1
2018 2
2019 2
2020 3
2021 2
2022 2
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.
Savas P, Lo LL, Luen SJ, Blackley EF, Callahan J, Moodie K, van Geelen CT, Ko YA, Weng CF, Wein L, Silva MJ, Bujak AZ, Yeung MM, Ftouni S, Hicks RJ, Francis PA, Lee CK, Dawson SJ, Loi S. Savas P, et al. Among authors: bujak az. Cancer Discov. 2022 Sep 2;12(9):2058-2073. doi: 10.1158/2159-8290.CD-21-1696. Cancer Discov. 2022. PMID: 35771551 Clinical Trial.
Lifelong aerobic exercise protects against inflammaging and cancer.
Nilsson MI, Bourgeois JM, Nederveen JP, Leite MR, Hettinga BP, Bujak AL, May L, Lin E, Crozier M, Rusiecki DR, Moffatt C, Azzopardi P, Young J, Yang Y, Nguyen J, Adler E, Lan L, Tarnopolsky MA. Nilsson MI, et al. Among authors: bujak al. PLoS One. 2019 Jan 25;14(1):e0210863. doi: 10.1371/journal.pone.0210863. eCollection 2019. PLoS One. 2019. PMID: 30682077 Free PMC article.
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
Dulak-Lis M, Bujak A, Gala K, Banach M, Kędzierska U, Miszkiel J, Hucz-Kalitowska J, Mroczkiewicz M, Stypik B, Szymczak K, Gunerka P, Dubiel K, Zygmunt BM, Wieczorek M, Pieczykolan JS. Dulak-Lis M, et al. Among authors: bujak a. J Pharmacol Sci. 2021 Apr;145(4):340-348. doi: 10.1016/j.jphs.2021.02.002. Epub 2021 Feb 9. J Pharmacol Sci. 2021. PMID: 33712286 Free article.
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.
Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ. Lok SW, et al. Among authors: bujak az. Cancer Discov. 2019 Mar;9(3):354-369. doi: 10.1158/2159-8290.CD-18-1151. Epub 2018 Dec 5. Cancer Discov. 2019. PMID: 30518523 Clinical Trial.
35 results